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Abundant evidence for translationwithin the 50 leaders of many human genes
is rapidly emerging, especially, because of the advent of ribosome profiling.
In most cases, it is believed that the act of translation rather than the encoded
peptide is important. However, the wealth of available sequencing data in
recent years allows phylogenetic detection of sequences within 50 leaders
that have emerged under coding constraint and therefore allow for the predic-
tion of functional 50 leader translation. Using this approach, we previously
predicted a CUG-initiated, 173 amino acid N-terminal extension to the
human tumour suppressor PTEN. Here, a systematic experimental analysis
of translation events in the PTEN 50 leader identifies at least two additional
non-AUG-initiated PTEN proteoforms that are expressed in most human cell
lines tested. The most abundant extended PTEN proteoform initiates at a con-
served AUU codon and extends the canonical AUG-initiated PTEN by 146
amino acids. All N-terminally extended PTEN proteoforms tested retain the
ability to downregulate the PI3K pathway. We also provide evidence for the
translation of two conserved AUG-initiated upstream open reading frames
within the PTEN 50 leader that control the ratio of PTEN proteoforms.
1. Introduction
The process of translation can be described in four steps: initiation,which is usually
tightly regulated; elongation; termination; and ribosome recycling [1]. In eukar-
yotes, the scanning model for translation initiation postulates that the small
ribosomal subunit, in complex with initiation factors and Met-tRNAi, binds first
to the 50 cap then scans 30 until a suitable initiation codon is found [2]. Base-pairing
interactions between the anticodon loop of the Met-tRNAi bound to the ribosome
and an AUG codon in the mRNA cause the ribosome to stop scanning and set the
reading frame for protein synthesis [3]. Typically, the ribosome initiates protein
synthesis at the AUG codon closest to the 50 end of the mRNA, though the effi-
ciency of initiation is dependent on the nucleotide sequence surrounding the
initiator codon with the optimal sequence known as the Kozak context [4]. The
Kozak context—comprising 6 nt before and 1 nt immediately following a potential
initiation codon—has significant influence on the recognition of an initiation site,
through partially understood mechanisms requiring the activities of eIF1 [5–8]
and eIF5 [9–11]. Using multiple sequence alignments, the consensus context
inmammalswas identified as GCCRCCAUGG [12] with the identity of the under-
lined nucleotides in the23 andþ4 positions (relative to the ‘A’ of the AUG) being
the most important. However, a recent high-throughput analysis of all possible
initiation contexts revealed RYMRMVAUGGC as the optimal context in human
and mouse cells and additionally revealed synergistic effects of neighbouring
nucleotides [13].
& 2016 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
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Initiation can occur at most codons that differ from AUG
by a single nucleotide (non-cognate or non-AUG). Seven out
of the nine possible single-nucleotide substitutions at the
AUG start codon of dihydrofolate reductase were functional
as translation start sites in mammalian cells [14]. In all of
the cases in which it was examined, the N-terminal residue
of these proteins was methionine [14], suggesting that trans-
lation initiation relied on mis-pairing between the anticodon
of Met-tRNAi and the non-AUG start codon in the mRNA.
However, a report exists of CUG initiation by elongator
Leu-tRNA functioning as initiator tRNA [15].
Initiation is the only step where an incoming aminoacyl
tRNA is bound directly in the ribosomal P-site [16,17]. Unlike
the A-site, where mRNA : tRNA interactions are strictly moni-
tored by the decoding centre [18], the P-site can tolerate
mismatches in the codon : anticodon duplex [19–22]. This
allows the incorporation of Met-tRNAi at a wider range of
codons compared with elongator Met-tRNA whose incorpor-
ation is strictly limited to AUG codons. The most favourable
context for non-AUG initiation is believed to be identical to
that for AUG starts [23–25]. In addition, a strong RNA second-
ary structure starting approximately 15 nt downstream of the
non-AUG codonmay significantly increase initiation efficiency
[26]. Another important factor for non-AUG initiation is that it
is located upstream of the most 50 AUG codon [27].
When initiation codons occur in the 50 leaders of tran-
scripts they give rise to either N-terminal extensions to the
main ORF or else upstream open reading frames (uORFs).
It has been estimated that AUG-initiated uORFs are present
in approximately half of the human protein coding genes
[28]. Furthermore, ribosome profiling provided evidence for
the presence of translating ribosomes on more than 200
non-AUG-initiated uORFs in yeast [29] and much more
widespread non-AUG initiation in mammals [30–32]. In gen-
eral, the translation of uORFs has an inhibitory effect on
translation of the main protein coding ORF, because ribo-
somes terminating a uORF are often unable to reinitiate
owing to the loss of necessary initiation factors. However,
the 40S subunits of ribosomes translating short ORFs (less
than 35 codons) may retain some initiation factors after ter-
mination [4,33]—although efficient re-initiation is precluded
until all necessary initiation factors have been reloaded onto
the 40S subunit. In most instances, there is a requirement
for a ternary complex of eIF2, GTP and Met-tRNAi which is
regulated by the phosphorylation status of eIF2a [34].
An earlier finding that sequences in the 50 leaders are
highly conserved and that the level of conservation globally
increases towards the leader/main ORF boundaries [35]
suggests that this conservation could be due, in part, to the 30
ends of a portion of 50 leaders encoding N-terminal extensions
to the annotated AUG-initiated proteins. In total, more than
60 instances of non-AUG-initiated N-terminal extensions
have been predicted or verified experimentally in mammals
[36–38]. In most cases, the non-AUG initiation provides an
alternative longer proteoform in addition to a proteoform
resulting from initiation at a standardAUGcodondownstream
via a process termed ‘leaky scanning’. Where alternative pro-
teoforms are produced as a result of leaky scanning, the
longer isoform frequently contains a signal for subcellular
localization that is absent in the shorter form [39–43].
Previously, we performed a systematic analysis of the 50 lea-
ders of human GenBank RefSeq mRNAs to investigate the
extent of non-AUG initiation in humans [37]. This involved
analysis of codon substitution rates in pairwise alignments of
human and mice orthologous sequences to identify regions
of 50 leaders evolving under the constraints of protein coding
evolution. When a region within a 50 leader evolves under
such constraints, it is very likely that the encoded protein can
improve an organism’s fitness and is thus functional. This
approach predicts a CUG-initiated, 173 amino acid, N-terminal
extensionwithin the 50 leader of phosphatase and tensin homologue
on chromosome ten (PTEN). PTEN is a powerful tumour suppres-
sor gene that encodes a dual-specificity phosphatase [44,45]
frequentlymutated in human cancers [46] and autism spectrum
disorders [47]. Its best characterized function is its ability to
negatively regulate cell survival by dephosphorylating phos-
phatidylinositol 3,4,5 triphosphate (PIP3) and thus inhibiting
phosphoinositide 3-kinase (PI3K) signalling [48].
Independently, two other groups subsequently identi-
fied the same PTEN N-terminal extension [49,50]. Here we
extended our analysis of the PTEN 50 leader and identify non-
AUG-initiated translation that leads to the synthesis of at least
two additional N-terminally extended proteoforms.
2. Material and methods
2.1. Plasmids
The PTEN 50 leader was amplified by PCR from HEK-293T
genomic DNA using appropriate primers (Integrated DNA
Technologies) that incorporated a 50 HindIII restriction site
and a 30 BamHI restriction site. PTEN 50 leaders were mutated
by two-step PCR with appropriately designed primers.
Amplicons were cloned HindIII/BamHI into the dual lucifer-
ase plasmid p2-Luc [51] such that the PTEN 50 leader replaced
the Renilla-encoding sequences and were fused directly to the
firefly-encoding sequences.
The coding sequence of PTEN was obtained as a gblock
(Integrated DNA Technologies) with incorporated 50 HindIII
and a 30 XbaI restriction site and cloned into phRL-CMV (Pro-
mega). The coding sequence of PTEN was also subcloned
downstream of the PTEN 50 leader to replace the firefly
encoding sequence of the PTEN 50 leader-FLuc constructs
made previously.
For PTEN 50 leader GFP fusions, EGFP was digested from
pEGFP-N3 (Clontech) with BamHI and XbaI restriction
enzymes and cloned BamHI/XbaI using standard cloning
techniques into the PTEN 50 leader firefly-encoding plasmids
described above, such that the EGFP sequence replaced the
firefly-encoding sequences and were fused directly to the
PTEN 50 leader. The EGFP AUG to AAA mutation was
made by two-step PCR with appropriately designed primers.
For signal peptide–Gaussia luciferase fusions, amplicons
generated by two-step PCR were cloned BamHI/XbaI into
pCMV-GLuc (NEB). All clones were verified by sequencing.
eIF1 and eIF5 overexpression constructs were described
previously [52,53].
2.2. Cell culture
HEK-293T, MDA-MB-231, MCF-7, HeLa, HUH-7, U2OS and
A172 cells were maintained in DMEM supplemented with
10% FBS, 1 mM L-glutamine and antibiotics. PC3 cells were
maintained in RPMI supplemented with 10% FBS, 1 mM
L-glutamine and antibiotics.
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2.3. Luciferase assay
HEK-293T cells were transfected with Lipofectamine 2000
reagent (Invitrogen), using the 1 day protocol in which sus-
pended cells are added directly to the DNA complexes in
full-area 96-well plates. For each transfection, the following
were added to each well: 100 ng of each firefly luciferase-
expressing plasmid, 10 ng of each Renilla luciferase-expressing
plasmid plus 0.4 ml Lipofectamine 2000 (Invitrogen) in 48.4 ml
Opti-Mem (Gibco). The transfecting DNA complexes in each
well were incubated with 4  104 cells suspended in 50 ml
DMEM (RPMI for PC3 cells) plus 10% FBS. Transfected cells
were incubated at 378C in 5% CO2 for 24 h. On the next day,
cells were washed once with 1  PBS and then lysed in 25 ml
of 1  passive lysis buffer (PLB; Promega) and firefly and
Renilla luciferase activities were determined using the Dual
Luciferase Stop & Glow Reporter Assay System (Promega).
Relative light units were measured on a Veritas Microplate
Luminometer with two injectors (Turner Biosystems).
Firefly luciferase activity was calculated relative to the
activity of the co-transfected control plasmid expressingRenilla
luciferase (pSV40-Renilla). All data points were averaged, and
the standard deviation calculated. Data represent themean and
standard deviation of at least three independent experiments
each done in quadruplicate.
For secretion luciferase assays (see figure 5c), only Gaussia
luciferase activities were assayed and the percentage activity
in both the cell lysate (intracellular) and culture media
(extracellular) calculated. For sodium arsenite treatment,
HEK-293T cellswere transfected as above, and sodium arsenite
(5 mM) was added 6 h post-transfection for either 2 or 4 h.
2.4. Immunoblotting
Cells were transfected in six-well plates using Lipofectamine
2000 reagent, again using the 1 day protocol described above,
with 1 mg of each indicated plasmid. Where FLuc- and
RLuc-expressing plasmids were cotransfected (see figure 6b
and electronic supplementary material, figure S10b) a ratio of
10 : 1 was used. The transfecting DNA complexes in each well
were incubated with 0.8  106 HEK-293T cells suspended in
3 ml DMEM plus 10% FBS and incubated overnight at 378C
in 5% CO2. Transfected cells were lysed in 100 ml 1  PLB and
10 ml removed for dual luciferase assay.
For PC3 transfections, 1.2  105 cells were plated in tripli-
cate wells (12-well plates) 1 day prior to forward transfection
with Lipofectamine 2000 reagent (4 ml) and 500 ng of each
indicated plasmid in 500 ml of Opti-Mem. Cells were replen-
ished with fresh RPMI media 6 h post-transfection, then after
18 h, cells were washed and treated with serum free RPMI for
a further 24 h. Transfected cells were lysed in radioimmuno-
precipitation assay (RIPA) buffer plus protease inhibitors
(Sigma) and NaF (20 mM).
Proteins were resolved by 4–12% gradient Bis/Tris–SDS/
PAGE (Bolt
TM
: Thermo Fisher Scientific) under constant voltage
(165 V) for 90 min and transferred to nitrocellulose membra-
nes (Protran), which were incubated at 48C overnight with
primary antibodies. Immunoreactive bands were detected on
membranes after incubation with appropriate fluorescen-
tly labelled secondary antibody using a LI-COR Odysseyw
Infrared Imaging Scanner. Densitometry analysis was per-
formed using IMAGEJ software (NIH) and GraphPad PRISM
used for statistical analysis.
2.5. Immunoprecipitation and GFP-trapw
Cells were lysed in RIPA buffer plus protease inhibitors
(Sigma), then lysates were incubated with 25 ml of protein
G agarose beads (Pierce) plus anti-PTEN (138G6) overnight
at 48C with gentle rocking. The beads were washed (three
times) with ice-cold RIPA buffer and then immunoprecipi-
tated proteins removed from the beads by boiling for 5 min.
in 20 ml of 2  SDS–PAGE sample buffer for electrophoresis
and immunoblotting.
GFP-trapw_A beads (ChromoTek) were equilibrated accord-
ing to the manufacturer’s protocol. For collection of the
extracellular fractions, culture medium was centrifuged at 200g
for 5 min at 48C to remove debris. For intracellular fractions,
cells were lysed in RIPA buffer as above. 10 ml of equilibrated
beads were added to each fraction and incubated rotating at
48C for 1 h. The beads were washed (three times) with ice-cold
dilution buffer (10 mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM
EDTA) and then immunoprecipitated proteins removed from
the beads by boiling for 10 min in 40 ml of 2  SDS–PAGE
sample buffer for electrophoresis and immunoblotting.
2.6. RT-qPCR
HEK-293T cells were transfected in triplicate wells (six-well
plate) as above with either construct 1 (wild-type PTEN
leader fused to firefly luciferase) or construct 5 (PTEN leader
with all uAUGs mutated to AGG). 24 h post-transfection cells
were removed (trypsin), divided into two aliquots of 20%
and 80% and then collected by centrifugation. 20% of cells
were resuspended in 20 ml 1  PLB for dual luciferase assay.
RNA was isolated using Trizol reagent (Invitrogen) from the
remaining 80% of cells, and 500 ng of DNAse-treated (RQ1:
Promega) RNA was reverse transcribed using oligo-dT and
randomhexamers according to themanufacturer’s instructions
(Superscritpt III: Invitrogen). Reactions minus reverse tran-
scriptase were included to control for contaminating genomic
or plasmid DNA. SYBR green (Qiagen) qPCR was performed
on anApplied Biosystems 7300 real-time PCR systemwith fire-
fly luciferase primers (sense TGGAGAGCAACTGCATAAGG
and antisense ATTCCGCGTACGTGATGTT) and a set of
intron-spanning control primers for GAPDH (sense AGCCT
CCCGCTTCGCTCTCT and antisense CCAGGCGCCCAA
TACGACCA). Relative RNA quantitation was analysed using
the Livak method (22DDCT ) and used to normalize relative
luciferase activities to relative RNA levels.
2.7. Antibodies
An affinity-purified rabbit polyclonal antibody (anti-PTEN-L)
directed to a predicted antigen (PRHQQLLPSLSSFFFSHR
LPD) within all four extended PTEN proteoforms was pre-
pared by GenScript. The following commercially available
antibodies were also used. Mouse anti-PTEN (6H2.1;
Millipore), rabbit anti-PTEN (138G6: Cell Signalling), rabbit
anti-GFP (A6455: Novex), goat anti-firefly luciferase (G7451:
Promega), rabbit anti-S473-phospho-AKT (D9E: Cell Signal-
ling), mouse anti-pan-AKT (40D4: Cell Signalling), mouse
anti-Renilla luciferase (1D5.2 Millipore), rabbit anti-eIF5
(ab85913: Abcam) and mouse anti-b-actin (AC-15: Sigma).
Anti-eIF1 was a generous gift from Ariel Stanhill
(Technion-Israel Institute of Technology).
rsob.royalsocietypublishing.org
Open
Biol.6:150203
3
 on March 28, 2018http://rsob.royalsocietypublishing.org/Downloaded from 
2.8. Fluorescence microscopy
Live cell imagingwas performed as described before [54] using
an inverted Axiovert 200 fluorescence microscope (Zeiss),
equipped with 100/1.4 Plan Apochromat oil-immersion
objective (Zeiss), pulsed excitation module (470 nm, 590 nm
LEDs), bandpass filters 510–560 nm and gated CCD camera
(LaVision, Biotec). Briefly, HeLa cells were seeded onto eight-
well chambers pre-coated with a mixture of collagen IV
and poly-D-lysine (Ibidi), allowed to attach (24 h) and forward
transfected for 24 h with plasmid DNAs encoding PTEN-
leader–GFP fusions as indicated. Images were processed
using IMSPECTOR software (LaVision, Biotec) and combined in
Adobe ILLUSTRATOR CS2.
3. Results
Previous searches for evolutionarily conserved non-AUG-
initiated N-terminal extensions in human coding sequences
predicted a CUG-initiated, 173 amino acid extension to the
tumour suppressor PTEN [37]. Further phylogenetic analysis
of the PTEN 50 leader with additional sequence data reveals
deep nucleotide conservation in mammals (figure 1a and elec-
tronic supplementary material, figure S1). Two independent
groups [49,50] have recently provided experimental evidence
for a human PTEN N-terminal extension that reportedly
initiates at the same CUG predicted by Ivanov et al. [37]. Pre-
liminary results in our laboratory indicated the existence of
multiple N-terminally extended PTEN proteoforms. Here we
set out to systematically investigate thesemultiple proteoforms
and also to determine the effect, if any, of two conservedAUG-
initiated uORFs on translation of these PTEN proteoforms
(boxed in figure 1a).
We noted that the 50 end of both GenBank RefSeq PTEN
mRNA isoforms (NM_000314.6, NM_001304718.1), which
have identical first exons, do not correspond to the transcrip-
tion start site predicted by the Fantom Projects’ CAGE
analysis [58] which finds that the transcription start site is a
further 187 nt 30 of the Genbank RefSeq annotated PTEN
mRNA 50 end (electronic supplementary material, figure S2).
A þ187 transcription start site is also in agreement with
mRNAseq data obtained as controls to multiple ribosome pro-
filing experiments, available in GWIPS-viz [59] (see electronic
supplementarymaterial, figure S2) as well as with the majority
of publicly available human PTEN expressed sequence tags.
Therefore, in this study, all test constructs with the PTEN 50
leader start at þ187 relative to the 50 end of GenBank RefSeq
PTEN mRNAs.
We first transfected HEK-293T cells with plasmid DNA
expressing the human PTEN 50 leader fused to sequences
encoding firefly luciferase (FLuc; figure 1b). Immunoblots gen-
erated from transfected cell lysates and probed with FLuc
antibodies detected four slower migrating FLuc proteoforms
when FLuc is preceded by the PTEN 50 leader (lane 2, top
panel, figure 1c). These four proteoforms are absent from
cells transfected with FLuc expressing constructs lacking the
PTEN 50 leader (lane 1, top panel, figure 1c) indicating that
the multiple proteoforms are not post-translationally modified
variants of FLuc. Furthermore, the same pattern of proteoforms
ATG
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firefly
firefly
firefly
ATGCTG
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TAA
L
L
L
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4
75 kDaL-FLuc
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Figure 1. (a) Sequence logo representation ( produced with WebLogo [55]) of a multiple sequence alignment of PTEN 50 leaders from 52 mammals. The alignment
was generated with CLUSTALX [56] and corrected manually. Asterisks indicate nucleotides conserved in all 52 species. Open black boxes represent two conserved
uORFs. Open green boxes indicate the main ORF AUG and previously predicted CUG initiation codons. (b) Illustration of transfected firefly luciferase constructs
1–4 used for immunoblotting. (c) Immunoblot of cell lysates prepared from HEK-293T cells transfected with firefly luciferase expressing constructs as indicated
and probed with antibodies against firefly luciferase (anti-FLuc: top panel), the PTEN N-terminal extension (anti-PTEN-L: middle panel) and b-actin (bottom panel).
The four proteoforms with extended PTEN N-termini are named as L, M, N and O. This nomenclature was recently proposed for novel PTEN proteoforms by Pulido
et al. [57]. Asterisk indicates a non-specific protein that co-migrates with the O-proteoform, thus precluding its detection with anti-PTEN-L. Lane 5 contains cell
lysates from mock-transfected cells.
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was also detected when these same lysates were probed with a
custom antibody (anti-PTEN-L) directed against a peptide pre-
dicted from sequences immediately 50 of, and in-frame with,
the PTEN main ORF (lane 2, middle panel, figure 1c).
These multiple proteoforms are most likely N-terminally
extended variants generated by initiation at in-frame non-
AUG codons within the PTEN 50 leader. Alternatively, some
of these proteoforms could be proteolytically cleaved variants
of the previously reported [49,50] CUG-initiated 173 amino
acid N-terminally extended PTEN proteoform. To investigate
this latter possibility, we transfected HEK-293T cells with
PTEN 50 leader-FLuc expressing constructs in which this CUG
was changed to either a non-initiating AGG triplet or to a
UAA stop codon, that not only prevents initiation but also
terminates translation from upstream initiation sites. Both
anti-FLuc and anti-PTEN-L immunoblots from these trans-
fected lysates indicate that mutation of the CUG leads to the
disappearance of only the most slowly migrating proteoform,
thus ruling out the possibility that some of the other proteo-
forms are cleavage products (lanes 3 and 4, top and middle
panels, figure 1c). These observations suggest that the PTEN 50
leader has the potential to generate at least four N-terminally
extended proteoforms (that are within the detection limits of
these experiments) and that the previously reported proteoform
initiated at CUG,while likely the longest proteoformmaynot be
the most abundant.
Because of the recent reporting of an N-terminally exten-
ded PTEN proteoform [37,49,50], a unified nomenclature
for PTEN proteoforms was proposed [57] where newly ident-
ified PTEN proteins are named alphabetically as PTEN-L,
PTEN-M, PTEN-N, etc. We have adopted this proposed
nomenclature and henceforth refer to these four PTEN iso-
forms as PTEN-L, PTEN-M, PTEN-N and PTEN-O, where
PTEN-L is the presumed longest variant and is initiated at
the previously reported CUG codon [37,49,50], whereas pro-
teoform PTEN-M appears to be the most abundant (table 1
and figure 1c).
It is conceivable that PTEN-M, PTEN-N and PTEN-O are
not non-AUG-initiated N-terminally extended proteoforms.
Instead, PTEN-M and PTEN-N could be post-translationally
modified variants of PTEN-O, whereas PTEN-N and PTEN-
O could be cleavage products of PTEN-M. To address these
possibilities, and to determine whether non-AUG initiation
could explain the presence of these proteoforms, we made
PTEN 50 leader-FLuc constructs in which potential non-
AUG initiation codons were systematically mutated in turn
to either AGG or UAA. Potential in-frame near-cognate
initiation codons from the relevant region within the PTEN
PTEN 5¢ leader
L-FLuc 75 kDa
anti-FLuc
anti-b-actin
50 kDa
M-FLuc
N-FLuc
O-FLuc
FLuc
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
firefly
(b)
(a)
Figure 2. (a) Illustration of human PTEN 50 leader fused to firefly luciferase and sequence of 50 leader region in which potential non-AUG codons are highlighted in
different colours with those in favourable Kozak context (23 purine and/or þ4 G) underlined. The previously reported CUG initiation site [37,49,50] is highlighted
in green and is the most 50 potential non-AUG initiation site. The PTEN CDS reading frame is indicated with spaces between the codons. (b) Anti-FLuc and anti-b-
actin immunoblots of cell lysates prepared from HEK-293T cells transfected with firefly luciferase encoding sequences fused to the wild-type or non-AUG codon
mutated (indicated) PTEN 50 leader. The four FLuc proteoforms with extended PTEN N-termini are indicated as L-, M-, N- and O-FLuc. In the control (CO, lane 16),
the main ORF (firefly) AUG is mutated to UAA.
Table 1. Details of PTEN N-terminally extended proteoforms. Nucleotide
distances from aAUG (annotated AUG of canonical PTEN) are indicated
where A of the aAUG is þ1.
nt from
aAUG
N-term
ext AA
total
nt
total
AA
MW
(kDa)
PTEN-L 2519 173 1728 576 64.9
PTEN-M 2438 146 1647 549 62.5
PTEN-N 2393 131 1602 534 61.0
PTEN-O 2216 72 1425 475 55.0
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50 leader are highlighted in figure 2a and those in a favourable
Kozak context (purine at 23 or G at þ4) are underlined.
Mutation of the most 50 in-frame AUU codon to AGG com-
pletely abolishes synthesis of the most prevalent proteoform
M-FLuc (lanes 4 and 5, figure 2b). As expected, mutation of
this AUU to a termination codon causes premature termin-
ation of L-FLuc (lane 5, figure 2b). It is difficult to be
certain about the nature of the initiation codon for N-FLuc,
because a cross-reacting endogenous protein migrates at the
same position; however, it seems likely that the second-
most 50 in-frame CUG is responsible as there is a clear
decrease in N-FLuc intensity when this CUG and all 30
non-AUGs are mutated individually to UAA (see lanes 9,
11, 13 and 15, figure 2b). Mutation of the most 30 in-frame
CUG completely abrogates expression of O-FLuc (lanes 14
and 15, figure 2b). In summary, the three minor proteoforms
(L, N and O) are all initiated at CUG, whereas the major
proteoform (M) is initiated at AUU.
We next tested for the existence of endogenous human
PTEN N-terminally extended proteoforms by immuno-
precipitating PTEN from several different cell lines using
commercially available antibodies directed against antigens
within the annotated PTEN (CDS). The predicted molecular
weight of PTEN is 47.2 kDa, but there are many reports indi-
cating that the apparent molecular weight of PTEN is
approximately 55 kDa. In agreement with this, immunoblots
of PTEN immunocomplexes reveal the presence of an approxi-
mately 55 kDa protein in all cell lines tested (figure 3a).
In addition to the canonical AUG-initiated PTEN, three
slower migrating proteins are observed in all cell lines
tested other than U2OS. The molecular weights of these three
proteins correlate well with those predicted for PTEN
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proteoforms PTEN-L, PTEN-M and PTEN-N. To determine
whether the migration of these putative endogenously
expressed PTEN N-terminally extended proteoforms correlate
with exogenously expressed proteoforms PTEN-L, PTEN-M
and PTEN-N (we could not detect any endogenous proteoform
that could correspond in molecular weight to PTEN-O in these
experiments), we transfected the human PTEN CDS fused to
either wild-type or mutated PTEN 50 leaders into A172 cells
which do not express endogenous PTEN. Immunoprecipitates
from transfected A172 cells were compared with immunopre-
cipitates from HEK-293T cells expressing endogenous PTEN
and show that exogenously expressed proteoforms PTEN-L,
PTEN-MandPTEN-Nco-migratewith endogenous PTENpro-
teins from HEK-293T cells (compare the first and fourth lanes
in figure 3b). Furthermore, in agreement with the FLuc reporter
constructs (figure 2b), mutation of the first and third in-frame
CUGs prevents initiation of the two minor PTEN proteoforms
PTEN-L and PTEN-N, whereas mutation of the first in-frame
AUU abolishes expression of the major PTEN-M proteoform
(figure 3b). Together, these results indicate that three slower
migrating PTEN proteoforms apparent in immunoprecipitates
from several cell lines correlate with non-AUG-initiated
proteoforms PTEN-L, PTEN-M and PTEN-N.
Several studies report that PTEN-L is an active phosphatase
and retains the ability to downregulate the PI3K pathway
[49,50,60–62]. To determine whether the PTEN proteoforms
described here are active phosphatases, we measured the phos-
phorylation status of the major PI3K substrate, AKT, in PC3
cells (no endogenous PTEN expression) transfected with
either wild-type or N-terminally extended PTEN proteoforms.
Exogenous expression of PTENreduced the levels ofAKTphos-
phorylation almost twofold, and similar levels of reduction
were observed for all four N-terminally extended proteoforms
(figure 4 and electronic supplementary material, figure S3).
Therefore, similar to previous observations for PTEN-L, the
phosphatase activities of PTEN-M, PTEN-N and PTEN-O are
not overtly affected by their N-terminal extensions.
N-terminal extensions often harbour signals for subcellu-
lar targeting or secretion. However, live cell imaging of AUG-
initiated PTEN N-terminal extensions fused to GFP reveal
diffuse cytoplasmic localization for all four PTEN–GFP
fusions indistinguishable from the localization of GFP alone
(electronic supplementary material, figure S4).
Hopkins et al. [49] suggest that the PTEN-L proteoform har-
bours anN-terminal signal peptide secretion signal andprovide
evidence that PTEN-L is secreted and can re-enter cells via a cell
re-entry motif similar to the HIV TAT protein. The predicted
amino acid sequences of PTEN-M and PTEN-N lack the puta-
tive secretion signal yet still retain the putative cell re-entry
motif (electronic supplementary material, figure S5) reported
by Hopkins et al. To rule out the possibility that the N-terminal
extension of PTEN-M might possess a cryptic signal peptide
sequence, we overexpressed, in HEK-293T cells, PTEN-L (as a
control) and PTEN-M N-terminal extensions fused to GFP
(same constructs as described in electronic supplementary
material, figure S4). A fusion of GFP with the signal peptide
sequence fromGaussia luciferase (GLuc) [63]wasused as a posi-
tive control (figure 5a). Extracellular and intracellular GFP
fusion proteins were concentrated by immunoprecipitation
using GFP-trapw (immobilized camelid anti-GFP antibody) fol-
lowed by immunoblotting with anti-GFP. Even though we
immunoblotted 50% of the total extracellular fraction and
only 5% of the intracellular fraction, we did not detect PTEN-
L-GFP or PTEN-M-GFP in the extracellular fraction (see lanes
1 and 3, middle panel, figure 5b). Furthermore, when HEK-
293T or U2OS cells were transfected with constructs expressing
either the PTEN-L or PTEN-M N-terminal extensions, or the
putative PTEN-L signal peptide alone, fused to GLuc, we
failed to detect GLuc activity in the cell media at levels above
background (figure 5c). Yet GLuc-fused downstream of the
PTEN-L N-terminal extension in which the putative PTEN-L
signal peptide was replaced with the signal peptide from
either GLuc or interleukin-2 efficiently targeted GLuc from
cells (figure 5c).
We next sought to ascertainwhether the non-AUG initiation
of the PTENproteoforms is regulated. The selection of poor con-
text initiation codons (including non-AUG start codons) is
modulated by intracellular levels of initiation factors eIF1
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Figure 4. (a) Illustration shows PTEN expressing constructs transfected into
PC3 cells. (b) Immunoblots of cell lysates prepared from PTEN-null PC3 cells
transfected with PTEN expressing constructs as indicated for 48 h (serum
starved for last 24 h) and probed with antibodies against PTEN (138G6),
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compared with the control sample. **p, 0.01, ***p, 0.001 by one-way
ANOVA followed by Tukey’s test.
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(increases stringency) and eIF5 (decreases stringency) [5–11,
52,53]. To determine whether initiation of the N-terminally
extended PTEN proteoforms are regulated by altered eIF1 or
eIF5 levels, we overexpressed each initiation factor separately
in HEK-293T cells and then immunoprecipitated endoge-
nous PTEN proteoforms (electronic supplementary material,
figure S6). Even though eIF1 and eIF5 levels are robustly
expressed, we note no discernible change in the ratio of PTEN
proteoforms compared with cells transfected with an empty
vector (electronic supplementary material, figure S6).
As shown in figure 1a, there are two conserved
AUG-initiated uORFs (uORF1 and uORF2) close to the
PTEN 50 cap (figure 6a and electronic supplementary material,
figure S7). The most 50 uORF (uORF1) is only four codons long
and starts with tandem AUG codons, both in good Kozak con-
text. uORF2 is much longer (45 codons) and also starts with a
good context AUG. Ribosomal profiling data compiled in
GWIPS-viz [59] for PTEN show a large number of ribosome
protected fragments aligning to uORF1 in comparison with
uORF2 (electronic supplementary material, figure S7). In gen-
eral, translation of uORFs has an inhibitory effect on main
ORF translation although this relationship between uORFs
and main ORFs is not so simple where multiple uORFs exist.
Usually, the translation of short uORFs is less inhibitory than
the translation of long uORFs, because the ribosomes’ ability
to reinitiate after translation of ORFs more than 35 codons is
normally greatly reduced (see Introduction). According to
the scanning model of eukaryotic translation initiation, we
would predict that the majority of scanning 43S complexes
would initiate uORF1; however, because it is only four
codons long, a high level of re-initiation is expected. Because
re-initiation is precluded until all necessary initiation factors
have reloaded onto the 40S, translation of uORF1 may favour
re-initiation at ORFs more 30 than uORF2. We set out to deter-
mine the possible role of these two uORFs on regulation of the
different PTEN proteoforms by transfecting HEK-293T cells
with PTEN 50-leader-FLuc reporter constructs in which the
uORFs were mutated and testing by dual luciferase assay
(figure 6a) and immunoblotting (figure 6b).
Even though we expect a high level of uORF1 translation,
mutation of the uORF1 tandem AUG codons to non-initiating
AGG codons has only a minor inhibitory effect (less than 10%)
on FLuc activity (compare construct 1 (wild-type PTEN 50
leader)with construct 2 in figure 6a).Mutating uORF1 is inhibi-
tory rather than stimulatory presumably because more
ribosomes now have access to uORF2 which we predict
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should be inhibitory. However, the fact that the inhibition
is only minor suggests that either uORF2 may not be as
inhibitory as we expect or that normally ribosomes translating
uORF1 can efficiently reinitiate uORF2. Another explanation
could be that in the wild-type context many ribosomes do not
initiate uORF1. However, mutation of the uORF1 stop codon
to a sense codon (extending the length of uORF1 to 161
codons) severely diminishes FLuc activity (construct 3,
figure 6a) which, in agreement with published ribosome profil-
ing data (electronic supplementary material, figure S7),
confirms that ribosomes do initiate at uORF1. A mutation that
disables uORF2 translation, either alone or in combination
with mutations that prevent uORF1 initiation, increased FLuc
activity more than twofold (compare construct 1 (wild-type)
with constructs 4 and 5 in figure 6a). This indicates that uORF2
is inhibitory and thus suggests that the level of re-initiation on
uORF2 is high. Similar results were observed in several other
cell lines tested, including breast carcinoma (MCF-7), prostate
carcinoma (PC3) and cervical carcinoma (HeLa; electronic sup-
plementary material, figure S8). In addition, there is little
difference in steady-state mRNA levels when both uORFs are
disabled (electronic supplementary material, figure S9).
In these reporter assays, it is assumed that the low level of
N-terminally extended proteoforms (relative to the main ORF)
have only a minor contribution to total FLuc activity. This is
supported by our own unpublished observations showing
that an AUG-initiated PTEN-L extension severely reduces
FLuc activity. To gain further understanding of the effect of
the uORFs on downstream translation, we performed anti-
FLuc immunoblots from cells transfected with constructs 1–6
(figure 6b and electronic supplementary material, figure S10).
Dual luciferase assays from replicate lysates show similar
FLuc activity for each construct to those shown in figure 6a
and electronic supplementary material, figure S8. Densitome-
try of the main ORF (FLuc) normalized to cotransfected RLuc
levels indicates that, similar to the luciferase assay results, pre-
venting initiation of the uORFs results in an almost twofold
increase in main ORF levels (figure 6c). Therefore, even
though levels of the N-terminally extended proteoforms
increase when uORF2 is mutated (lanes 4 and 5, figure 6b
and electronic supplementary material, figure S10), they have
only a minor contribution to overall FLuc activity. When
we estimate the levels of each N-terminally extended proteo-
form by densitometry, we observe that mutation of uORF2
causes the levels of the L and M/N proteoforms to increase
approximately 2.5-fold, the O proteoform to increase 2-fold,
whereas the main ORF increases approximately 1.5-fold.
Mutation of both uORFs together increases the L-proteoform
approximately 5.3-fold, M/N-proteoforms approximately
4.1-fold, O-proteoform approximately 3.1-fold and the main
ORF proteoform approximately 1.6-fold. This densitometry
analysis also allows us to estimate the relative abundance of
each proteoform under normal conditions and when ribo-
somes do not translate either or both uORFs. Interestingly,
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Figure 6. (a) Relative luciferase activities (FLuc/RLuc) of firefly encoding sequences fused to the wild-type or mutant PTEN 50 leader as indicated and cotransfected
(10 : 1 ratio) with a Renilla expressing plasmid into HEK-293T cells. Red crosses indicate mutation of AUG start codons to non-initiating AGG codons. L, M, N and O
depict the approximate site of initiation of PTEN extensions. The dashed box represents the increase in ORF length when the stop codon of uORF1 is changed to a
sense codon. (b) Anti-FLuc and anti-RLuc immunoblots of cell lysates prepared from HEK-293T cells transfected with Renilla and firefly luciferase expressing con-
structs indicated in (a). The four proteoforms with extended PTEN N-termini are indicated as L, M, N and O. CO represents lysates prepared from mock-transfected
cells. (c) Densitometry analysis from three biological replicates of the proteins detected by anti-FLuc and anti-RLuc in (b) and electronic supplementary material,
figure S10b. Proteoforms M and N could not be resolved sufficiently from each other for accurate densitometry analysis, so the intensity of both proteins together is
determined. FLuc intensities were calculated relative to RLuc.
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although all proteoforms increase when ribosomes do not
translate uORF2, the ratio of N-terminally extended proteo-
forms relative to each other does not change (electronic
supplementary material, figure S10c). In contrast, mutation of
uORF2 increases the ratio of N-terminal proteoforms relative
to the main ORF proteoform (electronic supplementary
material, figure S10d ) such that proteoforms M/N increase
by 50% from 12% to 18% of all proteoforms. Similar approxi-
mately 50% increases were also observed for the L- and O-
proteoforms (electronic supplementary material, figure S10d ).
Furthermore, there is a concomitant decrease in the relative
abundance of the main ORF proteoform from 83% down to
75%. Mutation of uORF1 and uORF2 together results in even
further increases to the relative abundance of N-terminally
extended proteoforms and further decreases the main ORF
proteoform (electronic supplementary material, figure S10d).
Because we show that translation of uORF2 can alter the
ratio of extended andmainORFproteoforms anduORF2 trans-
lation seems to be dependent on efficient re-initiation after
translation of uORF1, we predict that conditions which can
regulate re-initiation events could alter translation of the
main ORF. Increasing the phosphorylation status of eIF2
can reduce re-initiation by limiting the pool of functional
(non-phosphorylated) eIF2. To gain some understanding of
possible regulation of these uORFs, we transfected wild-type
and ‘no uAUG’ firefly reporters into HEK-293T cells and
then treated with sodium arsenite. Sodium arsenite activates
the integrated stress response by inducing phosphorylation
of eIF2. ManymRNAs (main ORFs) whose translation is resist-
ant to eIF2 phosphorylation harbour translated uORFs [64]. If
sodium arsenite decreased re-initiation on uORF2, then we
would expect to see an increase in FLuc activity with the
wild-type reporter; however, we observed little difference in
main ORF reporter translation upon sodium arsenite treatment
(electronic supplementary material, figure S11).
4. Discussion
The results presented above provide strong evidence for the
existence of three (or perhaps four) non-AUG-initiated proteo-
forms of PTEN that are expressed in human cells in addition to,
and at lower levels than, the well-studied canonical AUG-
initiated PTEN. The longest PTEN proteoform, PTEN-L,
has previously been reported [37,49,50] and its function has
been investigated in more detail in subsequent studies
[60,61,65–67]. However, PTEN-M, PTEN-N and PTEN-O
have not been previously described and are reported here for
the first time. We show that PTEN-M initiates at an AUU
codon that is completely conserved in 52 eutherian mamma-
lian species with available sequences, whereas the other
PTEN proteoforms (PTEN-L, PTEN-N and PTEN-O) initiate
at CUG, the first two also completely conserved while the
latter only partially conserved. CUG codons are generally
better initiators than AUU codons [14,52,53], so it is somewhat
surprising that AUU-initiated PTEN-M is more abundant than
CUG-initiated PTEN-L, especially, because the CUG is more 50
than the AUU. The PTEN-L CUG initiation codon Kozak con-
text is slightly less favourable (C at23 andG atþ4) than that of
the PTEN-MAUU initiation codon (A at23). It is also possible
that an as yet unidentified RNA secondary structure 30 of the
AUU codon contributes to its favourable utilization for
initiation (see Introduction), especially because the PTEN 50
leader is 70% GC rich with numerous potential stem-loops.
Yet another possibility is that the abundance of the PTEN pro-
teoforms is a reflection of differing protein stabilities rather
than initiation levels, although a similar level of exogenous
PTEN-L and PTEN-M expression when their non-AUGs
start codons are mutated to AUGs (figure 4b and electronic
supplementary material, figure S3) would argue against this.
The identity of the major non-AUG-initiated PTEN proteo-
forms identified in this study contrasts with the findings of
both Hopkins et al. [49] and Liang et al. [50], who both report
only a single CUG-initiated proteoform that corresponds
in our study to PTEN-L. Most of the anti-PTEN immunoblots
presented by Hopkins et al. show a single slower migrating
approximately 75 kDa PTEN proteoform which they term
PTEN-Long (PTEN-L in our study). A possible reason for
this discrepancy is that, in their study, proteins were separa-
ted for shorter time intervals while we purposely allowed
SDS–PAGE gels to run for extended periods (see Material
and methods) in an attempt to resolve as many PTEN proteo-
forms as technically possible. Perhaps the approximately
75 kDa PTEN-long detected by Hopkins et al. corresponds to
a mixture of unresolved PTEN-L, PTEN-M and PTEN-N.
Liang et al. similarly identify a PTEN proteoform
(PTEN-a) that initiates with the most 50 in-frame CUG and
corresponds to our PTEN-L and Hopkins et al. PTEN-Long.
Their anti-PTEN immunoblots from cells exogenously expres-
sing a PTEN-a construct clearly show two higher molecular
weight proteins in addition to PTEN. In agreement with
our study, mutation of the first in-frame CUG prevents trans-
lation of the longest protein. Furthermore, even when the first
and third CUG codons (PTEN-L and PTEN-N in our study)
are mutated together, an extended PTEN proteoform is still
apparent which is very likely to correspond to PTEN-M.
A recent report showing anti-PTEN immunoblots from
matched normal and tumour tissue samples clearly identifies,
in addition to canonical PTEN, at least two slower migrating
endogenous PTEN proteoforms expressed in a similar ratio to
PTEN-L and PTEN-M in our study [61].
When multiple proteoforms are translated from a single
mRNA, the efficiency of initiation at each start codon could
set the ratio of proteoform steady-state levels assuming each
protein has similar stability. However, this ratio may vary
during conditions in which initiation efficiency is altered.
Eukaryotes have developed elaborate mechanisms for the
recognition of the correct initiation codon and the levels of
certain initiation factors can regulate the fidelity of initiation,
especially on suboptimal (non-AUG and AUG in poor
context) start codons [52,53,68]. While elevated levels of eIF1
can increase the stringency of start codon selection, elevated
levels of eIF5 have the opposite effect. Here we show that over-
expression of either eIF1 or eIF5 had minimal effect on the
steady-state levels of PTEN proteoforms (electronic supplemen-
tary material, figure S6). This suggests that either the non-AUG
initiationevents inPTENare refractory to normal stringency con-
trols or the steady-state protein levels of these proteoforms are
regulated tightly by rapid turnover. An alternative explanation
is that because the PTEN 50 leader is long, the many potential
out-of-frame near-cognate codons could create uORFs and
thus preclude the expected effects of eIF1/5 overexpression on
translation of the PTEN N-terminal extensions.
Several groups have observed that PTEN-L can downregu-
late the PI3K pathway in a similar manner to PTEN [49,50,61].
In vitro studies comparing the catalytic activities of purified
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PTEN and PTEN-L reveal that both enzymes can dephosphory-
late PIP3, although, interestingly, PTEN phosphatase activity
can be activated by its reaction product (PIP2), whereas PTEN-
L cannot and is thus constitutively active [60,67]. We tested
whether the PTEN proteoforms identified in our study still
retained the ability to downregulate the PI3K pathway
(figure 4 and electronic supplementary material, figure S3). All
PTEN proteoforms were able to reduce AKT phosphorylation
to levels similar to those of canonical PTEN and PTEN-L,
suggesting that the N-terminal extensions do not have major
effects on the dephosphorylation activity of PTEN proteoforms.
Hopkins et al. [49] report that exogenously expressed PTEN-
L is targeted for secretion from cells by a predicted N-terminal
signal peptide and cleavage site. Furthermore, they also show
that immediately following the predicted cleavage site is a func-
tional cell re-entry signal similar to the HIV TAT protein [49].
Subsequently, Wang et al. [61] confirmed that PTEN-L, but
not PTEN, can enter cells, although whether PTEN-L can be
secreted from cells was not tested. Intriguingly, both PTEN-M
and PTEN-N, while lacking the predicted signal peptide, do
still retain the putative cell re-entry signal (electronic sup-
plementary material, figure S5). We overexpressed GFP fused
to both the PTEN-L (with putative secretion signal)
and PTEN-M N-terminal extensions but could not detect
PTEN-L-GFP in the cell culture media after concentrating by
immunoprecipitation (figure 5b). It is not so surprising that
PTEN-M-GFP is not found extracellularly because it lacks the
putative signal peptide, but failure to detect PTEN-Lwas unex-
pected and suggests that most PTEN-L is not secreted. It is
possible that this assay was not sensitive enough to detect
low levels of secreted PTEN-L-GFP, so we further tested
whether a secretion signal resided in the PTEN-L extension
by fusing the PTEN 50 leader to Gaussia luciferase. Gaussia luci-
ferase is approximately 1000 times more sensitive than either
Renilla or firefly luciferases [69], yet we could not detect any
extracellular luciferase activity, above background, in con-
structs harbouring the putative PTEN-L signal peptide
(figure 5c). One explanation for the discrepancy between our
PTEN localization experiments and those of previous studies
is that, because canonical PTEN has been found in exosomes
[70,71] and can homodimerize [72], we decided to make repor-
ters that do not contain sequences encoding the canonical PTEN
CDS. Perhaps the important targeting signals are only ‘visible’
in the context of the full-length PTEN proteins. Yet another
possible explanation for not detecting our PTEN-L chimeras
in the cell culture media could be that the efficiency of cell re-
entry is extremely high. However, detection of extracellular
luciferase activity when the PTEN-L signal peptide is replaced
with either theGaussia luciferase or interleukin-2 signal peptide
would argue against this possibility (figure 5c).
The functional significance of the PTEN-M N-terminal
extension has yet to be determined but perhaps some insight
may be gained fromprevious studies onPTEN-L. There are con-
flicting reports as to whether the PTEN-L extension has the
potential to form a three-dimensional structure [60,67] or
whether it is intrinsically disordered [65,66]. A recent elegant
HDX-MS approach by Masson et al. [62] indicates that while
most of the PTEN-LN-terminal extension is indeed intrinsically
disordered, there is a potential a-helix at position 151–174
(where residue 174 is the methionine encoded by the canonical
PTENAUG). This peptide is protected by liposomes, suggesting
an interaction with the membrane. Furthermore, this potential
membrane-spanning region alters both the interfacial kinetics
of PTEN-L and the protein/membrane interface, causing
PTEN-L to function on membranes in a ‘scooting’ mode rather
than a ‘hopping’ mode that is characteristic of PTEN [62]. All
N-terminally extended proteoforms described in our study pos-
sess this potential a-helix so it will be interesting to see whether
these new PTEN proteoforms act in a similar manner. It is
perhapsnoteworthy thatwe couldnot detect PTEN-Oby immu-
noprecipitationwith PTEN antibodies, presumably because this
N-terminal extension (andnot L,MandN) alters protein confor-
mation in a manner that prevents antibody access to the PTEN
antigen under native conditions. This suggests possible struc-
tural differences between the PTEN-O N-terminal extension
and the other PTEN proteoforms.
In our analysis of the conserved PTEN uORFs, we initially
hypothesized that translation of uORF1 could reduce trans-
lation of uORF2, which, because of its size (45 codons), we
expect to be severely inhibitory for downstream translation.
In this way, translation of uORF1 could, in theory, have an
overall positive effect on main ORF translation by reducing
the number of ribosomes accessing the predicted inhibitory
uORF2. However, intriguingly, increasing the number of ribo-
somes accessing uORF2 by mutation of uORF1 appears not to
be very inhibitory under the conditions tested (figure 6). There-
fore, we conclude that either uORF1 is frequently passed by
leaky scanning, which seems unlikely given the evidence we
described previously for uORF1 translation, or ribosomes
translating uORF1 can re-initiate efficiently at uORF2. Alterna-
tively, similar results would be observed if uORF2 were not
very inhibitory (i.e. permits high level re-initiation). However,
when ribosomes do not translate uORF2, downstream trans-
lation increases approximately 2.5-fold at the CUG of the
L-proteoform in comparison with when uORF2 is available
for translation (figure 6b,c). As one would predict from the
scanning model of translation initiation, removal of both
uORFs further increases the level of downstream initiation a
further twofold (for L-FLuc). Importantly, the presence of
uORF2 affects the ratio of N-terminally extended proteoforms
relative to the main ORF, but has no effect on the ratio of
N-terminally extended proteoforms to each other (electronic
supplementary material, figure S10c,d).
These reporter assay results raise the intriguing possibility
that the deeply conserved uORFs in the PTEN 50 leader may
become less inhibitory for PTEN translation under, as yet uni-
dentified, conditions that could either decrease elongation
rates, which in theory would result in ribosome accumulation
along uORFs and hamper scanning, or else downregulate re-
initiation. There is evidence that the canonical mTOR–S6K
pathway regulates re-initiation after uORFs in plants [73].
We predict that such regulation could have dramatic effects
on the abundance of N-terminally extended proteoforms,
especially if initiation of both uORFs were reduced.
These findings, together with the findings on PTEN-L
from other groups, could have profound implications for
the interpretation of previous studies on both the catalytic
activity and localization of endogenous PTEN as well as
the analysis of polymorphisms within the PTEN 50 leader.
Furthermore, the discovery of these new PTEN proteo-
forms could have implications for the development of
PTEN-based chemotherapeutic agents.
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